Hitomi Morishima

Publication Activity (10 Years)

Years Active: 2018-2021
Publications (10 Years): 3

Top Topics

Patient Reported

Monoclonal Antibody

End Stage Renal Disease

Placebo Controlled

Top Venues

The Journal of dermatology

This page only lists publications with an associated author ORCID identifier.

Publications

Yukari Okubo, Hitomi Morishima, Richuan Zheng, Tadashi Terui
Sustained efficacy and safety of guselkumab in patients with palmoplantar pustulosis through 1.5 years in a randomized phase 3 study. The Journal of dermatology 48 (12) (2021)
Mamitaro Ohtsuki, Hiroshi Kubo, Hitomi Morishima, Ryosuke Goto, Richuan Zheng, Hidemi Nakagawa
Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study. The Journal of dermatology 45 (9) (2018)
Shigetoshi Sano, Hiroshi Kubo, Hitomi Morishima, Ryosuke Goto, Richuan Zheng, Hidemi Nakagawa
Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study. The Journal of dermatology 45 (5) (2018)